Telix Pharmaceuticals is trading 4.02% down at $11.83, with no clear company-specific catalyst emerging on August 14, 2026.
- The latest investor update concerns the scheduled August 20 half-year results release, rather than a new announcement explaining the decline.
- Broader U.S. indexes are slightly higher, so the movement does not appear to track broad market weakness.